{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T16:27:27Z","timestamp":1777307247013,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.rmed.2023.107196","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T21:20:03Z","timestamp":1678137603000},"page":"107196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["The role of riociguat in combination therapies for pulmonary arterial hypertension"],"prefix":"10.1016","volume":"211","author":[{"given":"Franck F.","family":"Rahaghi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Giovanna","family":"Trivieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0672-1680","authenticated-orcid":false,"given":"Sandeep","family":"Sahay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.rmed.2023.107196_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01889-2018","article-title":"Risk stratification and medical therapy of pulmonary arterial hypertension","volume":"53","author":"Gali\u00e8","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2023.107196_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/thoraxjnl-2015-207170","article-title":"The molecular targets of approved treatments for pulmonary arterial hypertension","volume":"71","author":"Humbert","year":"2016","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.rmed.2023.107196_bib3","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.pharmthera.2013.10.002","article-title":"Targeted therapies in pulmonary arterial hypertension","volume":"141","author":"Montani","year":"2014","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.rmed.2023.107196_bib4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/bph.15016","article-title":"Current and future treatments of pulmonary arterial hypertension","volume":"178","author":"Sommer","year":"2021","journal-title":"Br. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.rmed.2023.107196_bib5","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.rmed.2023.107196_bib6","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S2213-2600(16)00027-8","article-title":"Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis","volume":"4","author":"Lajoie","year":"2016","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2023.107196_bib7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40256-017-0262-z","article-title":"Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from the randomized controlled GRIPHON study","volume":"18","author":"Coghlan","year":"2018","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"6","key":"10.1016\/j.rmed.2023.107196_bib8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1164\/rccm.201908-1640OC","article-title":"Combination therapy with oral treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial","volume":"201","author":"White","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"9","key":"10.1016\/j.rmed.2023.107196_bib9","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.rmed.2023.107196_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2045894020942121","article-title":"Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)","volume":"10","author":"Ghofrani","year":"2020","journal-title":"Pulm. Circ."},{"issue":"4","key":"10.1016\/j.rmed.2023.107196_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2045894020962960","article-title":"Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension","volume":"10","author":"Sitbon","year":"2020","journal-title":"Pulm. Circ."},{"issue":"1","key":"10.1016\/j.rmed.2023.107196_bib12","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01908-2018","article-title":"Clinical trial design and new therapies for pulmonary arterial hypertension","volume":"53","author":"Sitbon","year":"2019","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2023.107196_bib13","first-page":"2200879","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"30","author":"Humbert","year":"2022","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.rmed.2023.107196_bib14","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S2213-2600(20)30532-4","article-title":"Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial","volume":"9","author":"Hoeper","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2023.107196_bib15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.rmed.2023.107196_bib16","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2023.107196_bib17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-2600(16)30019-4","article-title":"Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial","volume":"4","author":"Ghofrani","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2023.107196_bib18","series-title":"Adempas US Prescribing Information","author":"Bayer","year":"2021"},{"key":"10.1016\/j.rmed.2023.107196_bib19","series-title":"Adempas EU summary of product characteristics","author":"Bayer","year":"2021"},{"issue":"5","key":"10.1016\/j.rmed.2023.107196_bib20","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1183\/09031936.00105914","article-title":"PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in PAH","volume":"45","author":"Gali\u00e8","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.rmed.2023.107196_bib21","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.chest.2016.05.024","article-title":"Riociguat: mode of action and clinical development in pulmonary hypertension","volume":"151","author":"Ghofrani","year":"2017","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.rmed.2023.107196_bib22","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1111\/bcp.14676","article-title":"Riociguat: clinical research and evolving role in therapy","volume":"87","author":"Klinger","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"13","key":"10.1016\/j.rmed.2023.107196_bib23","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1111\/bph.14205","article-title":"PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery","volume":"175","author":"Andersson","year":"2018","journal-title":"Br. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.rmed.2023.107196_bib24","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1164\/rccm.202009-3698OC","article-title":"Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension","volume":"204","author":"Boucly","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.rmed.2023.107196_bib25","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00299-2020","article-title":"Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension","volume":"6","author":"Kjellstr\u00f6m","year":"2020","journal-title":"ERJ. Open Res."},{"issue":"1","key":"10.1016\/j.rmed.2023.107196_bib26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s41030-019-00106-4","article-title":"Retrospective database analysis of treatment patterns among patients with pulmonary arterial hypertension","volume":"6","author":"Studer","year":"2020","journal-title":"Pulm. Ther."},{"issue":"14","key":"10.1016\/j.rmed.2023.107196_bib27","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jacc.2021.07.057","article-title":"Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension","volume":"78","author":"Chin","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.rmed.2023.107196_bib28","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1164\/rccm.202004-1006OC","article-title":"Risk reduction and hemodynamics with initial combination therapy in pulmonary arterial hypertension","volume":"203","author":"Badagliacca","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.rmed.2023.107196_bib29","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02425-2016","article-title":"RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors","volume":"50","author":"Hoeper","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.rmed.2023.107196_bib30","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.healun.2016.12.012","article-title":"Comparison of hemodynamic parameters in treatment-na\u00efve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study","volume":"36","author":"Gali\u00e8","year":"2017","journal-title":"J. Heart Lung Transplant."},{"issue":"1","key":"10.1016\/j.rmed.2023.107196_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2045894019826944","article-title":"Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension","volume":"9","author":"Sulica","year":"2019","journal-title":"Pulm. Circ."},{"issue":"5","key":"10.1016\/j.rmed.2023.107196_bib32","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.healun.2022.01.002","article-title":"Upfront riociguat and ambrisentan combination therapy for newly diagnosed pulmonary arterial hypertension: a prospective open-label trial","volume":"41","author":"Weatherald","year":"2022","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.rmed.2023.107196_bib33","article-title":"Riociguat treatment in patients with pulmonary arterial hypertension: final safety data from the EXPERT registry","volume":"177","author":"Hoeper","year":"2020","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2023.107196_bib34","series-title":"Pulmonary Hypertension Association 2022 International Conference and Scientific Sessions, June 9\u201312, Atlanta, GA, USA","article-title":"Rationale and design of the RiOciguAt UseRs (ROAR) Registry","author":"Sulica","year":"2022"},{"issue":"1","key":"10.1016\/j.rmed.2023.107196_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2045894020910098","article-title":"Real-world experience using combination therapy with riociguat and risk assessment using REVEAL Lite 2.0 in patients with pulmonary arterial hypertension","volume":"10","author":"Sahay","year":"2020","journal-title":"Pulm. Circ."},{"issue":"2","key":"10.1016\/j.rmed.2023.107196_bib36","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.chest.2019.09.009","article-title":"Risk reduction and right heart reverse remodeling by upfront triple combination therapy in pulmonary arterial hypertension","volume":"157","author":"D'Alto","year":"2020","journal-title":"Chest"},{"issue":"26","key":"10.1016\/j.rmed.2023.107196_bib37","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.rmed.2023.107196_bib38","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1183\/09031936.00116313","article-title":"Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study","volume":"43","author":"Sitbon","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2023.107196_bib39","doi-asserted-by":"crossref","DOI":"10.1177\/1753466621995048","article-title":"Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension","volume":"15","author":"Momoi","year":"2021","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"4","key":"10.1016\/j.rmed.2023.107196_bib40","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40256-018-0272-5","article-title":"Pulmonary arterial hypertension: combination therapy in practice","volume":"18","author":"Burks","year":"2018","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"2","key":"10.1016\/j.rmed.2023.107196_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12055","article-title":"Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat","volume":"12","author":"Rahaghi","year":"2022","journal-title":"Pulm. Circ."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611123000847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611123000847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T11:29:43Z","timestamp":1746098983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611123000847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":41,"alternative-id":["S0954611123000847"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2023.107196","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of riociguat in combination therapies for pulmonary arterial hypertension","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2023.107196","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107196"}}